Effect of chronic ritonavir administration on pregnant rats and their fetuses

Clinical and Experimental Obstetrics and Gynecology

Volumn 31, Issue 3, 2004, Pages 229-231

  Carvalho, A M ^a,c   Oliveira Filho, R M ^b   Simoes M J ^b   Amed, A A ^b   Kulay Jr , L ^b  

^a Univ Jose Rosario Vellano Sch Med   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c School of Medicine   (Brazil)

Author keywords

Pregnancy; Rat; Ritonavir; Toxicology

Indexed keywords

DRUG VEHICLE; GLYCOPROTEIN P; PROPYLENE GLYCOL; RITONAVIR;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FEMALE FERTILITY; FETUS DEATH; FETUS WEIGHT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL MORTALITY; MORTALITY; NIDATION; NONHUMAN; PLACENTA WEIGHT; PREGNANCY; PRENATAL DRUG EXPOSURE; PROTEIN DETERMINATION; RAT; VIRUS TRANSMISSION; WEIGHT GAIN;

ANIMALS; FEMALE; FETAL RESORPTION; HIV PROTEASE INHIBITORS; INFERTILITY, FEMALE; PREGNANCY; RANDOM ALLOCATION; RATS; RATS, WISTAR; RITONAVIR; WEIGHT GAIN;

EID: 4644299465     PISSN: 03906663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hogg R.S., O'Shaughnessy M.V., Gataric N., Yip B., Craib K., Schechter M.T., Montaner J.S.: "Decline in deaths from AIDS due to new antiretrovirals". Lancet, 1997, 349, 1294.
2. Selik R.M., Karon J.M., Ward J.W.: "Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993". J. Infect. Dis., 1997, 176, 632.
3. Palella F.J. Jr., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A. et al.: "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection". N. Engl. J. Med., 1998, 338, 853.
4. Murphy S.L.: "Deaths: final data for 1998". Natl. Vital. Stat. Rep., 2000, 48, 1.
5. Kumar G.N., Rodríguez A.D., Buko A.M., Denissen J.F.: "Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes". J. Pharmacol. Exp. Ther., 1996, 277, 423.
6. Koudriakova T., Iatsimirskaia E., Utkin I., Gang E., Vouros P., Storozhuk E. et al.: "Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P450 3A4/3A5: mechanism based inactivation of cytochrome P450 by ritonavir". Drug. Metab. Dispos., 1998, 26, 552.
7. Von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Duan S.X., Fogelman, S.M. et al.: "Protease inhibitors as inhibitors of human cytochromes P 450: high risk associated with ritonavir". J. Clin. Pharmacol., 1998, 38, 106.
8. Kumar G.N., Jennifer D., Roberts E.M., Jayanti V.K., Hickman D., Uchic J. et al.: "Potent inhibition of the cytochrome P-450 3A4 mediated human liver microsomal metabolism of novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction". Drug. Metab. Dispos., 1999, 27, 902.
9. Kempf D.J., Marsh K.C., Kumar G., Rodrigues A.D., Denissen J.F., McDonald E.M. et al.: "Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir". Antimicrob. Agents. Chemother., 1997, 41, 654.
10. Walmsley S., Berstein B., King M., Arribas J., Beall G., Ruane P. et al.: "Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection". N. Engl. J. Med., 2002, 346, 2039.
11. Danner S.A., Carr A., Leonard J.M., Lehman L.M., Gudiol F., Gonzales J. et al.: "A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease". N. Engl. J. Med., 1995, 333, 1528.
12. Lewis J.S., Terriff C.M., Coulston D.R., Garrison M. W.: "Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus". Clin. Ther., 1997, 19, 187.
13. Minkoff H., Augenbraun M.: "Antiretroviral therapy for pregnant women". Am. J. Obstet. Gynecol., 1997, 176, 478.
14. Denissen J.F., Grabowski B.A., Johnson M.K., Buko A.M., Krempf D.J., Thomas S.B., Surber B.W.: "Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans". Drug. Metab. Dispos., 1997, 25, 489.
15. Yamaji H., Matsumura Y., Yoshikawa Y., Takada K.: "Pharmacokinetic interactions between HIV-protease inhibitors in rats". Bioph. Drug. Disp., 1999, 20, 241.
16. Mirochnick M., Dorenbaum A., Holland D., Cunningham-Schrader B., Cunningham C., Gelber R. et al: "Concentrations of protease inhibitors in cord blood after in utero exposure". Pediatr. Infect. Dis. J., 2002, 21, 835.
17. Hamilton J.B., Wolfe J.M.: "The effect of male hormone substance upon birth and prenatal development in the rat". Anat. Rec., 1938, 70, 433.
18. Sokal R.R., Rohlf F.J.: "Biometry". San Francisco, W.H. Freeman, ed., 1969, 776.
19. Siegel S.: "Estadística no paramétrica". México, Ed. Trillas, 1975, 346.
20. Jackson A.A., Robinson S.M.: "Dietary guidelines for pregnancy: a review of current evidence". Public. Health. Nutr., 2001, 4, 625.
21. Carr A., Samaras K., Chisholm D.J., Cooper D.A.: "Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance". Lancet. 1998, 352, 1881.
22. Gagnon A., Angel J.B., Sorisky A.: "Protease inhibitors and adipocyte differentiation in cell culture". Lancet, 1998, 352, 1032.
23. Stricker R.B., Goldberg B.: "Fat accumulation and HIV-1 protease inhibitors". Lancet, 1998, 35, 1392.
24. Martinez E., Gatelli J.M.: "Metabolic abnormalities and body fat redistribution in HIV-1infected patients: the lipodystrophy syndrome". Curr. Op. Infec. Dis., 1999, 12, 13.
25. Batterham M., Garsia R., Greenop P.: "Prevalence and predictors of HIV-associated weight loss in the era of highly active antiretroviral therapy". Int. J. STD. AIDS. 2002, 13, 744.
26. Silva M., Skolnik P.R., Gorbach S.L., Spiegelman D., Wilson I.B., Fernández-DiFranco M.G., Knox T.A.: "The effect of protease inhibitors on weight and body composition in HIV-infected patients". AIDS, 1998, 12 (11), 1645.
27. Tsiodras S., Mantzoros C., Hammer S., Samore M.: "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study". Arch. Intern. Med. 2000, 160, 2050.
28. Vernochet C., Azoulay S., Duval D., Guedj R., Ailhaud G., Dani C.: "Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation". AIDS, 2003, 17 (15), 2177.
29. Huisman M.T., Smit J.W., Wiltshire H.R., Hoetelmans R.M., Beijnen J.H., Schinkel A.H.: "P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir". Mol. Pharmacol., 2001, 59, 806.
30. Mirochnick M.: "Antiretroviral pharmacology in pregnant women and their newborns". Ann. NY. Acad. Sci., 2000, 918, 287.